Holly Millet
Family · Gramercy, LANPI 1124658745
Payments from drug & device makers
Across 162 payments — averaging $18.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$761
- Novartis$181
- Astellas Pharma US Inc$166
- Bayer$165
- GSK$161
- Otsuka America Pharmaceutical, Inc.$159
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,96097%
- Education$793%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 45 | $761 |
| Novartis | 10 | $181 |
| Astellas Pharma US Inc | 6 | $166 |
| Bayer | 7 | $165 |
| GSK | 9 | $161 |
| Otsuka America Pharmaceutical, Inc. | 8 | $159 |
| Pfizer | 9 | $159 |
| Axsome Therapeutics, Inc. | 7 | $149 |
| Lilly USA, LLC | 8 | $123 |
| Ardelyx, Inc. | 4 | $99 |
| Novo Nordisk | 6 | $90 |
| Merck | 6 | $86 |
| Alpha Cognition USA, Inc. | 2 | $73 |
| Amgen | 4 | $71 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $69 |
| Lundbeck LLC | 3 | $59 |
| Vertex | 2 | $54 |
| Boehringer Ingelheim | 3 | $49 |
| Johnson & Johnson | 3 | $48 |
| Dexcom, Inc. | 2 | $48 |
| Teva Pharmaceuticals USA, Inc. | 2 | $47 |
| Vanda Pharmaceuticals Inc. | 2 | $36 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Gilead | 1 | $21 |
| AstraZeneca | 1 | $21 |
| Cranial Technologies, Inc | 1 | $20 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$3,039 in reported general payments places this provider in the 80th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 110 | $100,900 |
| MounjaroTirzepatide | 67 | $68,147 |
| OzempicSemaglutide | 50 | $50,276 |
| LinzessLinaclotide | 54 | $34,814 |
| TrulicityDulaglutide | 38 | $28,867 |
| JanuviaSitagliptin Phosphate | 24 | $27,372 |
| RexultiBrexpiprazole | 37 | $27,344 |
| FarxigaDapagliflozin Propanediol | 46 | $26,244 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $17,258 |
| KerendiaFinerenone | 18 | $16,334 |
| TradjentaLinagliptin | 13 | $9,728 |
| EliquisApixaban | 16 | $6,966 |
| Tresiba Flextouch U-100Insulin Degludec | 14 | $6,035 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 66 | $5,906 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 99 | $2,700 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $49 | $110,627123 claims |
| Lilly USA, LLCMounjaro, Trulicity | $123 | $97,014105 claims |
| Novo NordiskOzempic | $90 | $50,27650 claims |
| AbbVieLinzess | $761 | $34,81454 claims |
| MerckJanuvia | $86 | $27,37224 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $159 | $27,34437 claims |
| AstraZenecaFarxiga | $21 | $26,24446 claims |
| GSKTrelegy Ellipta | $161 | $17,25827 claims |
| BayerKerendia | $165 | $16,33418 claims |
| PfizerEliquis | $159 | $6,96616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,610 family providers in Louisiana.
Other family in Gramercy
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
- Tiffany RoeShreveport$97K
- Ghenet GhebretatiosBaton Rouge$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.